Portfolio Update

RNS Number : 1669L
Intl. Biotechnology Trust PLC
11 May 2022
 

 

11 May 2022

 

 

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

 

 

Portfolio Update as at 11 May 2022

 

The Company notes that Pfizer Inc (PFE) has announced that it entered a definitive agreement to acquire IBT's portfolio company Biohaven Pharmaceutical Holding Company Ltd (Biohaven or BHVN) for $148.50 per share which represents a 74% premium to the share price of Biohaven preceding the announcement. At the time of the announcement, IBT owned 182k shares in Biohaven which represented c.5.2% of IBT's Net Asset Value. The uplift in IBT's NAV attributable to this event is 3.55%.

 

For further information contact:

 

 

Company Secretary - Link Company Matters

 

Indu Shastri  +44 (0)7936 045789

 

LEI: 213800N1QUJ744P76D11

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUBUGDULSBDGDB

Companies

International Biotech Trust (IBT)
Investor Meets Company
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today